Monitoring Agency Report for the quarter ended 31st March 2025
GRASIM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings, the monitoring agency, has submitted its report on Grasim Industries' Rights Issue for Q4 FY25 (quarter ended March 31, 2025). The Rs. 3,999.80 crore rights issue (offered at Rs. 1,812 per share in January 2024 and subscribed 1.97 times) has been fully deployed with no deviation from stated objects. Of the Rs. 3,977.65 crore planned, Rs. 3,000 crore was used to repay term loans and Rs. 967.26 crore was used for general corporate purposes, specifically repaying commercial paper. During Q4 FY25 alone, Rs. 2,001.17 crore was utilized. Promoter shareholding marginally rose from 42.75% (pre-issue) to 43.11% post-issue.
This is a routine compliance filing confirming disciplined use of the rights issue proceeds entirely toward debt repayment, which should help lower the company's interest burden. No deviation and full deployment of funds are mildly positive signals for shareholders, though there is no direct stock price catalyst.